Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioXcel TherapeuticsBTAI +5.09%10 Cash Ratio is 0.09 as of Jun. 2026, which is 98% below its 10-year median of 4.91. GuruFocus rates BTAI with a GF Score™ of 10/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 946 Drug Manufacturers companies, BioXcel Therapeutics ranks worse than 85.62% on this metric.
BioXcel Therapeutics has a Cash Ratio of 0.09. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for BioXcel Therapeutics's Cash Ratio or its related term are showing as below:
BTAI'
s Cash Ratio Range Over the Past 10 Years
Min: 0.09 Med: 4.91 Max: 36.25
Current: 0.09
During the past 10 years, BioXcel Therapeutics's highest Cash Ratio was 36.25. The lowest was 0.09. And the median was 4.91.
BTAI's Cash Ratio is ranked worse than 85.62% of 946
companies
in the Drug Manufacturers industry
Industry Median: 0.58
vs BTAI: 0.09
BioXcel Therapeutics (NAS:BTAI) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BioXcel Therapeutics Cash Ratio Related Terms
BioXcel Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BTAI) has a Cash Ratio of 0.09 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioXcel Therapeutics and its competitors. This is 98% below median its historical median of 4.91. Over the past decade, BioXcel Therapeutics' Cash Ratio has ranged from 0.09 to 36.25. According to the industry distribution chart, BioXcel Therapeutics ranks #810 out of 946 companies in the Drug Manufacturers industry, placing it in the top 85.6%.
Is BioXcel Therapeutics' Cash Ratio too high?
BioXcel Therapeutics' current Cash Ratio of 0.09 is 98% below median its 10-year median of 4.91. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 36.25. The Drug Manufacturers industry median Cash Ratio is 0.58. BioXcel Therapeutics' value of 0.09 is 84.5% below this industry median. Based on the distribution chart, BioXcel Therapeutics ranks #810 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioXcel Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Cash Ratio compare to MRMD and RMTI?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #810 out of 946 companies for Cash Ratio. This places BioXcel Therapeutics in the lower half of its industry. The industry median Cash Ratio is 0.58. BioXcel Therapeutics' value of 0.09 is 84.5% below this benchmark. Historically, BioXcel Therapeutics' own Cash Ratio has ranged from 0.09 to 36.25 over the past decade. While the company's 10-year median is 4.91 vs. the industry median of 0.58, BioXcel Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.58, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioXcel Therapeutics's current Cash Ratio of 0.09 is 84.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioXcel Therapeutics and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current Cash Ratio is 0.09, which is 98% below median its own 10-year median of 4.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $0.79 — trading 45.4% above its estimated fair value. The current Cash Ratio is 0.09, which is 98% below median its 10-year median of 4.91 and 84.5% below the Drug Manufacturers industry median of 0.58. BioXcel Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Cash Ratio is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (BTAI) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of $0.79 is trading 45.4% above its estimated GF Value™ of $0.54.
GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.
Key valuation signals for BTAI:
Cash Ratio: 0.09 (98% below median its 10-year median of 4.91)
GF Value™: $0.54 vs. price of $0.79 (45.4% above fair value)
Industry Position: 84.5% below the Drug Manufacturers median (#810 of 946)
No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
10GF Score
Get the complete analysis for BTAI
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAI has been successfully added to your 
